Vieworks
Vieworks VXCAD-CXR.
Vieworks has announced that its diagnostic aid solution, utilising artificial intelligence (AI), has received certification from the Ministry of Food and Drug Safety (MFDS). Developed by the imaging solution provider’s affiliated research institute, VXCAD-CXR can detect three types of chest diseases.
The solution works by analysing radiography images of the chest to suggest areas of suspected disease or potential abnormalities. Information regarding the probability of occurrence and the lesion site of Pleural Effusion, Pneumothorax, and Nodules are communicated to allow medical staff to provide results.
“In line with the increasing demand for emergency medical services and the sophisticated healthcare market, developing AI-based diagnostic aids for medical device companies is becoming a necessity, not an option,” said Hooshik Kim, CEO of Vieworks. “We will continue to create high-added value and innovate medical imaging solutions using our in-house development capabilities as a driving force.”
Looking forward to the future, Vieworks hopes to expand the diagnosis range of the solution to include consolidation and pneumonia. Additionally, the company is looking to diversify its diagnostic aid solutions line-up, which will start with the acquisition of the domestic license for VXCAD-CXR. Vieworks will also introduce CAD and two deep learning-based noise reduction technologies.
A Vieworks representative said, “We will increase our market share by showcasing our existing hardware strengths, such as X-ray detectors, along with diagnostic aids optimised for them.”